Table 1.
Summary of patients’ clinical, biological and therapeutic characteristics and its association with BCL2 level.
| Characteristics | BCL2-Dx Continuous | BCL2-Dx Dichotomous | |||
|---|---|---|---|---|---|
| Mean | p Value | High BCL2 (%) | p Value | ||
| Median age at diagnosis (years)(range) | 59 (16-82) | 0.317 | |||
| Sex (n (%)) | |||||
| Female | 73 (41.5) | 0.543 | 62.90 | 0.063 | |
| Male | 103 (58.5) | 37.10 | |||
| WBC per µL | |||||
| Mean (range) | 6900 (900–41.2 × 104) | 0.304 | |||
| Cytogenetic risk (n (%)) | |||||
| Low | 13 (7.4) | 1.37 | 0.587 | 58.30 | 0.839 |
| Intermediate | 122 (69.3) | 1.59 | 77.70 | ||
| High | 38 (21.6) | 1.81 | 70.00 | ||
| Unknown | 3 (1.7) | ||||
| ELN risk category (n (%)) | |||||
| Low | 37 (21.0) | 1.39 | 0.345 | 67.60 | 0.283 |
| Intermediate | 66 (37.5) | 1.61 | 76.30 | ||
| High | 57 (32.4) | 1.75 | 78.40 | ||
| Unknown | 16 (9.1) | ||||
| NPM1 (n (%)) | |||||
| Wild type | 128 (72.7) | 1.7 | 0.052 | 74.60 | 1 |
| Mutated | 41 (23.3) | 1.38 | 74.40 | ||
| Unknown | 7 (4) | ||||
| FLT3-ITD (n (%)) | |||||
| Wild type | 139 (79) | 1.63 | 0.77 | 73.00 | 0.471 |
| Mutated | 31 (17.6) | 1.56 | 82.10 | ||
| Unknown | 6 (3.4) | ||||
| Therapy (n (%)) | |||||
| Intensive induction therapy: anthracycline + cytarabine | 166 (94.9) | ||||
| Other | 9 (5.1) | ||||
| Induction response (n (%)) | |||||
| Complete remission | 89 (53.9) | 1.55 | 0.116 | 72.30 | 0.778 |
| Primary refractory disease | 66 (40) | 1.81 | 83.10 | ||
| Exitus | 10 (6) | 1.4 | 55.60 | ||
| Relapsed disease (n (%)) | 57 (32.4) | ||||
| Allogeneic HCT in consolidation (n (%)) | |||||
| No | 91 (64.1) | 1.53 | 0.811 | 73.20 | 0.672 |
| Yes | 51 (29) | 1.58 | 77.30 | ||
| Exitus | |||||
| No | 59 (33.5) | 1.51 | 0.469 | 64.70 | 0.415 |
| Yes | 117 (66.5) | 1.65 | 78.80 | ||
Dx, diagnosis; WBC, white blood cells; ELN, European LeukemiaNet 2010; SD, standard deviation; n, number of cases; HCT, hematopoietic stem cell transplantation.